Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis

Cao Mingkun; Yinyuxia; Wang Zhiyong; Zhang Haijun

doi:doi:10.11648/j.ijcm.20220601.12

| Peer-Reviewed

Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis

Cao Mingkun, Yinyuxia, Wang Zhiyong, Zhang Haijun

Published in International Journal of Chinese Medicine (Volume 6, Issue 1)

Received: 1 September 2021 Accepted: 16 September 2021 Published: 28 January 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: Drug- eluting balloon (DEB) and drug- eluting stent (DES) are widely used in cardiovascular interventional surgery. But the long-term safety of DEB is unclear. Objective: To compare the efficacy and safety of DEB with DES for the treatment of de novo coronary artery disease (CAD). Methods: We conducted a meta-analysis of relevant studies identified in the Pubmed, Embase, and Cochrane Library databases. Random and fixed effects models were used to calculate the relative risks (RR) and standard mean differences (SMD) with 95% confidence intervals. Results: Nine studies in 1946 patients were included in this analysis. There was no significant difference in the primary endpoint of major adverse cardiovascular events (MACE) or in the efficacy endpoint of late lumen loss (LLL) between the DEB and DES groups. For follow-up < 12 months, there was no significant difference between DEB and DES for each MACE component, including target lesion revascularization (TLR), stent thrombosis (ST), myocardial infarction (MI), and death. However, a lower risk for MI and death was observed for DEB when the follow-up time was ≥ 12 months. Conclusion: DEB is equivalent to DES for the treatment of patients with de novo CAD and appears to represent a safer option for long-term treatment of this patient population.

Published in	International Journal of Chinese Medicine (Volume 6, Issue 1)
DOI	10.11648/j.ijcm.20220601.12
Page(s)	8-14
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Drug-eluting Balloon, Drug-eluting Stent, De Novo Coronary Artery Disease

References

[1]	Katsanos K, Spiliopoulos S, Kitrou P, et al (2018) Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association 7: e011245.
[2]	Stone GW, Ellis SG, Cannon L, et al (2005) Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. Jama 294: 1215-1223.
[3]	Bangalore S, Kumar S, Fusaro M, et al (2012) Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 125: 2873-2891.
[4]	Lasala JM, Cox DA, Lewis SJ, et al (2009) Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 5: 67-77.
[5]	Kirtane AJ, Ellis SG, Dawkins KD, et al (2008) Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. Journal of the American College of Cardiology 51 (7): 708-715.
[6]	Chang M, Park DW (2014) Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer? Cardiol Ther 3: 1-12.
[7]	Hung MJ, Hsu KH, Chang NC, Tsimikas S, Hung MY (2015) Prevalence of coronary artery spasm after stent placement and its association with inflammation. International journal of cardiology 179: 252-255.
[8]	Costa F, Ariotti S, Valgimigli M, Kolh P, Windecker S (2015) Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization: Fifty Years of Revascularization: Where Are We and Where Are We Heading? Journal of cardiovascular translational research 8: 211-220.
[9]	Siontis GCM, Stefanini GG, Mavridis D, et al (2015) Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. The Lancet 386: 655-664.
[10]	Byrne RA, Joner M, Alfonso F, Kastrati A (2014) Drug-coated balloon therapy in coronary and peripheral artery disease. Nature reviews Cardiology 11: 13-23.
[11]	Higgins JP, Altman DG, Gotzsche PC, et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed) 343: d5928.
[12]	Wells GA, Shea B, O'Connel D, et al. NewCastle-Ottawa Quality Assessment Scale –Cohort Studies. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
[13]	Sinaga DA, Ho HH, Watson TJ, et al (2016) Drug-Coated Balloons: A Safe and Effective Alternative to Drug-Eluting Stents in Small Vessel Coronary Artery Disease. Journal of interventional cardiology 29: 454-460.
[14]	Her AY, Kim YH, Garg S, Shin ES (2018) Impact of paclitaxel-coated balloon versus newer-generation drug-eluting stent on periprocedural myocardial infarction in stable angina patients. Coronary artery disease 29: 403-408.
[15]	Sim HW, Ananthakrishna R, Chan SP, et al (2018) Treatment of Very Small De Novo Coronary Artery Disease With 2.0 mm Drug-Coated Balloons Showed 1-Year Clinical Outcome Comparable With 2.0 mm Drug-Eluting Stents. The Journal of invasive cardiology 30: 256-261.
[16]	Ali RM, Degenhardt R, Zambahari R, et al. (2011) Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 7 Suppl K: K83-92.
[17]	Latib A, Colombo A, Castriota F, et al (2012) A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. Journal of the American College of Cardiology 60: 2473-2480.
[18]	Latib A, Ruparelia N, Menozzi A, et al (2015) Long-term (3-year) follow-up of the balloon elution and late loss optimisation (BELLO) study. JACC Cardiovasc Interv 8: 1132-1134.
[19]	Cortese B, Micheli A, Picchi A, et al (2010) Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart (British Cardiac Society) 96: 1291-1296.
[20]	Gobić D, Tomulić V, Lulić D, et al (2017) Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention: a Feasibility Study. American journal of the medical sciences 354: 553-560.
[21]	Jeger RV, Farah A, Ohlow MA, et al (2018) Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. The Lancet 392: 849-856.
[22]	Nishiyama N, Komatsu T, Kuroyanagi T, et al (2016) Clinical value of drug-coated balloon angioplasty for de novo lesions in patients with coronary artery disease. International journal of cardiology 222: 113-118.
[23]	Sabate M, Raber L, Heg D, et al (2014) Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. JACC Cardiovascular interventions 7: 55-63.
[24]	Palmerini T, Biondi-Zoccai G, Riva DD, et al (2012) Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. The Lancet 379: 1393-1402.
[25]	Habib A, Finn AV (2015) Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. Pharmacological research 93: 22-27.
[26]	DeSilvey DL (2007) Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. The American journal of geriatric cardiology 16: 115-116.
[27]	Scheller B, Hehrlein C, Bocksch W, et al (2008) Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clinical research in cardiology: official journal of the German Cardiac Society 97: 773-781.
[28]	Rittger H, Brachmann J, Sinha AM, et al (2012) A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. Journal of the American College of Cardiology 59: 1377-1382.
[29]	Kleber FX, Harald R, Klaus B, et al (2013) Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clinical Research in Cardiology Official Journal of the German Cardiac Society 102: 785-797.
[30]	Nakatani M, Takeyama Y, Shibata M, et al (2003) Mechanisms of restenosis after coronary intervention: Difference between plain old balloon angioplasty and stenting. Cardiovascular Pathology 12: 40-48.
[31]	Chae IH, Yoon CH (2017) Comparison of Drug-Eluting Balloon Followed by Bare Metal Stent with Drug-Eluting Stent for Treatment of de Novo Lesions: Randomized, Controlled, Single-Center Clinical Trial 32: 933-941.
[32]	Clever YP, Cremers B, Speck U, Dietz U, Bohm M, Scheller B (2014) Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions 84: 323-331.
[33]	Poerner TC, Otto S, Gassdorf J, et al (2014) Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up. Circulation Cardiovascular interventions 7: 760-767.
[34]	Vos NS, Dirksen MT, Vink M, et al (2014) Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 10: 584-590.
[35]	Liu L, Liu B, Ren J, et al (2018) Comparison of drug-eluting balloon versus drug-eluting stent for treatment of coronary artery disease: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 18: 46.
[36]	Kang IS, Shehata I, Shin DH, et al (2016) Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation. Heart and vessels 31: 1405-1411.
[37]	Mamuti W, Jiamali A, Rao F, et al (2014) Drug-coated balloon angioplasty for drug-eluting stent restenosis: insight from randomized controlled trials. Annals of medicine 46: 679-683.
[38]	Mehilli J, Jochheim D (2015) Paclitaxel-Coated Balloon for Recalcitrant In-Drug-Eluting Stent Restenosis. JACC Cardiovascular interventions 8: 1701-1703.
[39]	Windecker S, Kolh P, Alfonso F, et al (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European heart journal 35: 2541-2619.

Cite This Article

Plain Text BibTeX RIS

APA Style

Cao Mingkun, Yinyuxia, Wang Zhiyong, Zhang Haijun. (2022). Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis. International Journal of Chinese Medicine, 6(1), 8-14. https://doi.org/10.11648/j.ijcm.20220601.12

Copy | Download

ACS Style

Cao Mingkun; Yinyuxia; Wang Zhiyong; Zhang Haijun. Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis. Int. J. Chin. Med. 2022, 6(1), 8-14. doi: 10.11648/j.ijcm.20220601.12

Copy | Download

AMA Style

Cao Mingkun, Yinyuxia, Wang Zhiyong, Zhang Haijun. Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis. Int J Chin Med. 2022;6(1):8-14. doi: 10.11648/j.ijcm.20220601.12

Copy | Download

@article{10.11648/j.ijcm.20220601.12,
  author = {Cao Mingkun and Yinyuxia and Wang Zhiyong and Zhang Haijun},
  title = {Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis},
  journal = {International Journal of Chinese Medicine},
  volume = {6},
  number = {1},
  pages = {8-14},
  doi = {10.11648/j.ijcm.20220601.12},
  url = {https://doi.org/10.11648/j.ijcm.20220601.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcm.20220601.12},
  abstract = {Background: Drug- eluting balloon (DEB) and drug- eluting stent (DES) are widely used in cardiovascular interventional surgery. But the long-term safety of DEB is unclear. Objective: To compare the efficacy and safety of DEB with DES for the treatment of de novo coronary artery disease (CAD). Methods: We conducted a meta-analysis of relevant studies identified in the Pubmed, Embase, and Cochrane Library databases. Random and fixed effects models were used to calculate the relative risks (RR) and standard mean differences (SMD) with 95% confidence intervals. Results: Nine studies in 1946 patients were included in this analysis. There was no significant difference in the primary endpoint of major adverse cardiovascular events (MACE) or in the efficacy endpoint of late lumen loss (LLL) between the DEB and DES groups. For follow-up Conclusion: DEB is equivalent to DES for the treatment of patients with de novo CAD and appears to represent a safer option for long-term treatment of this patient population.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis
AU  - Cao Mingkun
AU  - Yinyuxia
AU  - Wang Zhiyong
AU  - Zhang Haijun
Y1  - 2022/01/28
PY  - 2022
N1  - https://doi.org/10.11648/j.ijcm.20220601.12
DO  - 10.11648/j.ijcm.20220601.12
T2  - International Journal of Chinese Medicine
JF  - International Journal of Chinese Medicine
JO  - International Journal of Chinese Medicine
SP  - 8
EP  - 14
PB  - Science Publishing Group
SN  - 2578-9473
UR  - https://doi.org/10.11648/j.ijcm.20220601.12
AB  - Background: Drug- eluting balloon (DEB) and drug- eluting stent (DES) are widely used in cardiovascular interventional surgery. But the long-term safety of DEB is unclear. Objective: To compare the efficacy and safety of DEB with DES for the treatment of de novo coronary artery disease (CAD). Methods: We conducted a meta-analysis of relevant studies identified in the Pubmed, Embase, and Cochrane Library databases. Random and fixed effects models were used to calculate the relative risks (RR) and standard mean differences (SMD) with 95% confidence intervals. Results: Nine studies in 1946 patients were included in this analysis. There was no significant difference in the primary endpoint of major adverse cardiovascular events (MACE) or in the efficacy endpoint of late lumen loss (LLL) between the DEB and DES groups. For follow-up Conclusion: DEB is equivalent to DES for the treatment of patients with de novo CAD and appears to represent a safer option for long-term treatment of this patient population.
VL  - 6
IS  - 1
ER  -

Copy | Download

Author Information

Cao Mingkun

National United Engineering Laboratory for Biomedical Material Modification, Dezhou, China
Yinyuxia

National United Engineering Laboratory for Biomedical Material Modification, Dezhou, China
Wang Zhiyong

Inner Mongolia People's Hospital, Hohhot, China
Zhang Haijun

National United Engineering Laboratory for Biomedical Material Modification, Dezhou, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Cao Mingkun, Yinyuxia, Wang Zhiyong, Zhang Haijun. (2022). Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis. International Journal of Chinese Medicine, 6(1), 8-14. https://doi.org/10.11648/j.ijcm.20220601.12

Copy | Download

ACS Style

Cao Mingkun; Yinyuxia; Wang Zhiyong; Zhang Haijun. Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis. Int. J. Chin. Med. 2022, 6(1), 8-14. doi: 10.11648/j.ijcm.20220601.12

Copy | Download

AMA Style

Cao Mingkun, Yinyuxia, Wang Zhiyong, Zhang Haijun. Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis. Int J Chin Med. 2022;6(1):8-14. doi: 10.11648/j.ijcm.20220601.12

Copy | Download

@article{10.11648/j.ijcm.20220601.12,
  author = {Cao Mingkun and Yinyuxia and Wang Zhiyong and Zhang Haijun},
  title = {Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis},
  journal = {International Journal of Chinese Medicine},
  volume = {6},
  number = {1},
  pages = {8-14},
  doi = {10.11648/j.ijcm.20220601.12},
  url = {https://doi.org/10.11648/j.ijcm.20220601.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcm.20220601.12},
  abstract = {Background: Drug- eluting balloon (DEB) and drug- eluting stent (DES) are widely used in cardiovascular interventional surgery. But the long-term safety of DEB is unclear. Objective: To compare the efficacy and safety of DEB with DES for the treatment of de novo coronary artery disease (CAD). Methods: We conducted a meta-analysis of relevant studies identified in the Pubmed, Embase, and Cochrane Library databases. Random and fixed effects models were used to calculate the relative risks (RR) and standard mean differences (SMD) with 95% confidence intervals. Results: Nine studies in 1946 patients were included in this analysis. There was no significant difference in the primary endpoint of major adverse cardiovascular events (MACE) or in the efficacy endpoint of late lumen loss (LLL) between the DEB and DES groups. For follow-up Conclusion: DEB is equivalent to DES for the treatment of patients with de novo CAD and appears to represent a safer option for long-term treatment of this patient population.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis
AU  - Cao Mingkun
AU  - Yinyuxia
AU  - Wang Zhiyong
AU  - Zhang Haijun
Y1  - 2022/01/28
PY  - 2022
N1  - https://doi.org/10.11648/j.ijcm.20220601.12
DO  - 10.11648/j.ijcm.20220601.12
T2  - International Journal of Chinese Medicine
JF  - International Journal of Chinese Medicine
JO  - International Journal of Chinese Medicine
SP  - 8
EP  - 14
PB  - Science Publishing Group
SN  - 2578-9473
UR  - https://doi.org/10.11648/j.ijcm.20220601.12
AB  - Background: Drug- eluting balloon (DEB) and drug- eluting stent (DES) are widely used in cardiovascular interventional surgery. But the long-term safety of DEB is unclear. Objective: To compare the efficacy and safety of DEB with DES for the treatment of de novo coronary artery disease (CAD). Methods: We conducted a meta-analysis of relevant studies identified in the Pubmed, Embase, and Cochrane Library databases. Random and fixed effects models were used to calculate the relative risks (RR) and standard mean differences (SMD) with 95% confidence intervals. Results: Nine studies in 1946 patients were included in this analysis. There was no significant difference in the primary endpoint of major adverse cardiovascular events (MACE) or in the efficacy endpoint of late lumen loss (LLL) between the DEB and DES groups. For follow-up Conclusion: DEB is equivalent to DES for the treatment of patients with de novo CAD and appears to represent a safer option for long-term treatment of this patient population.
VL  - 6
IS  - 1
ER  -

Copy | Download